- Home
- ANGO vs IMMP Comparison
ANGO vs IMMP Comparison
Compare ANGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- IMMP
- Stock Information
- Founded
- ANGO 1988
- IMMP 1987
- Country
- ANGO United States
- IMMP Australia
- Employees
- ANGO N/A
- IMMP N/A
- Industry
- ANGO Medical/Dental Instruments
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- IMMP Health Care
- Exchange
- ANGO Nasdaq
- IMMP Nasdaq
- Market Cap
- ANGO 279.1M
- IMMP 304.0M
- IPO Year
- ANGO 2004
- IMMP N/A
- Fundamental
- Price
- ANGO $11.94
- IMMP $1.91
- Analyst Decision
- ANGO Strong Buy
- IMMP Buy
- Analyst Count
- ANGO 3
- IMMP 2
- Target Price
- ANGO $13.00
- IMMP $8.50
- AVG Volume (30 Days)
- ANGO 849.3K
- IMMP 95.6K
- Earning Date
- ANGO 01-08-2025
- IMMP 02-27-2025
- Dividend Yield
- ANGO N/A
- IMMP N/A
- EPS Growth
- ANGO N/A
- IMMP N/A
- EPS
- ANGO N/A
- IMMP N/A
- Revenue
- ANGO $286,498,000.00
- IMMP $2,563,302.00
- Revenue This Year
- ANGO N/A
- IMMP N/A
- Revenue Next Year
- ANGO $7.69
- IMMP $47.79
- P/E Ratio
- ANGO N/A
- IMMP N/A
- Revenue Growth
- ANGO N/A
- IMMP 9.59
- 52 Week Low
- ANGO $5.26
- IMMP $1.66
- 52 Week High
- ANGO $13.13
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ANGO 64.64
- IMMP 40.99
- Support Level
- ANGO $11.65
- IMMP $2.00
- Resistance Level
- ANGO $12.96
- IMMP $2.05
- Average True Range (ATR)
- ANGO 0.69
- IMMP 0.09
- MACD
- ANGO 0.16
- IMMP -0.02
- Stochastic Oscillator
- ANGO 72.83
- IMMP 2.78
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.